Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 35

Results For "PLI"

3732 News Found

Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL
Drug Approval | February 25, 2026

Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL

Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older


CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC
Clinical Trials | February 25, 2026

CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC

Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity


Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ
News | February 25, 2026

Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ

The innovative eyedrop targets inflammation and pain following ocular surgery


Lupin launches generic Brivaracetam oral solution in US to treat epilepsy
News | February 25, 2026

Lupin launches generic Brivaracetam oral solution in US to treat epilepsy

Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB


India shifts focus from 'Pharmacy of the World' to 'Global Innovation Hub', says Health Minister Nadda
Policy | February 24, 2026

India shifts focus from 'Pharmacy of the World' to 'Global Innovation Hub', says Health Minister Nadda

Nadda underlined that India’s policy framework is aligned with this transformation


Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D
R&D | February 24, 2026

Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D

The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform


Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy
Drug Approval | February 24, 2026

Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy

If approved, DTX401 would be the first treatment to address the disease at its root cause


Novo Nordisk’s
Clinical Trials | February 24, 2026

Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks

UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies


FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL
Drug Approval | February 23, 2026

FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL

The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years


PharmEasy integrates with Samsung Health to streamline digital healthcare
Digitisation | February 23, 2026

PharmEasy integrates with Samsung Health to streamline digital healthcare

Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership